Abbott to acquire Exact Sciences in a $23bn deal.

Abbott, a global healthcare company, agreed to acquire Exact Sciences, a molecular diagnostics company, in a $23bn deal. "Exact Sciences' innovation, its strong brand and customer-focused execution are unrivaled in the cancer diagnostics space, and its presence and strengths are complementary to our own. Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious diseases. We're excited to bring Exact Sciences' people and know-how into Abbott so that together, we can take on the global challenge of cancer," Robert B. Ford, Abbot Chairman and CFO.